While Bollywood stars are busy launching skincare brands, Marksans Pharma decided to launch “Tariff Survival Kit” instead. Q1 FY26 came with its own plot twist: U.K. drama, U.S. tariffs, and employees costing more than Bollywood endorsements. But hey, the company is still cash-rich, debt-free, and armed with a Goa factory that sounds more like a five-star resort than a pharma plant. Stick around—things get juicier than a cough syrup overdose.
2. At a Glance
Revenue up 5% – Growth, but not the blockbuster the CFO ordered.
Gross Margin up 209 bps – Magic trick: old inventory gone, cheaper stuff in.
EBITDA margin shrunk 560 bps – HR costs and one-time ECL ate the ladoos.
PAT down 34.7% – Profits vanished faster than UK’s summer.
Cash ₹711 Cr, Debt-free – Pharma monk mode: zero leverage, lots of cash.
3. Management’s Key Commentary
Quote: “Q1 was seasonally soft, impacted by UK price erosion and integration expenses.” (Translation: Blame weather, tariffs, and a bad horoscope. Actual execution? Don’t ask.)
Quote: “We launched 4 high-margin products in the UK.” (Translation: Revenue meh, but at least margins on paper look photogenic.)
Quote: “Working capital cycle at 159 days due to front-loading U.S. shipments.” (Translation: Customers got pills early, but cash decided to take a vacation.)
Quote: “Our Goa facility is near ready with multi-dosage capability.” (Translation: Goa is no longer just for beaches—it’s for capsules, creams, and corporate dreams.)
Quote: “We remain debt-free with ₹711 Cr cash.” (Translation: At least the balance sheet is fitter than the P&L.)
Quote: “Gross margins improved due to softening input costs.” (Translation: Cheaper raw materials saved the quarter—Mother Nature did what cost control couldn’t.)
Quote: “We may be shy of ₹3,000 Cr revenue target.” (Translation: Targets are like New Year resolutions—nice on PowerPoint, reality says otherwise.)
4. Numbers Decoded
Metric
Value (Q1 FY26)
YoY Change
One-Line Analysis
Revenue – The Hero
₹620 Cr
+5%
Barely flexed; growth feels like a diet plan.
Gross Profit – Cushion
₹358.2 Cr
+8.9%
Margins fluffed thanks to low-cost inventory.
EBITDA – Sidekick
₹100.1 Cr
-22%
Shrunk under HR + ECL baggage.
EBITDA Margin – Drama
16.1%
-560 bps
Needs therapy; too sensitive to one-offs.
PAT – The Vanisher
₹58.2 Cr
-34.7%
Profits ghosted like UK customers.
Cash Balance – Monk
₹711 Cr
Flat
Rich but stingy; refuses to touch debt.
Working Capital Cycle
159 days
Up
Pills shipped early, cash came late.
5. Analyst Questions
Q: Why did UK fall 20%? A: Seasonality + desperate competitors selling cheap. (Translation: The Brits chose discounts over prescriptions.)
Q: How about U.S. orders? A: $220M book intact, execution starts Oct-Dec. (Translation: Future revenue is like Marvel sequels—promised, delayed, hyped.)
I had a lot of fun reading this article!! (and of course the information I need).